Home > Healthcare > Pharmaceuticals > Vaccines > Tetanus Toxoid Vaccine Market

Tetanus Toxoid Vaccine Market Trends

Report ID: GMI8301
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Tetanus Toxoid Vaccine Market Trends

Product launches and collaborations play significant roles in driving innovation and expanding access to tetanus toxoid vaccines, thereby contributing to the growth of the tetanus toxoid vaccine industry.

Pharmaceutical companies frequently launch new and improved versions of tetanus toxoid vaccines to address evolving medical needs and technological advancements. These product launches introduce innovative formulations, delivery systems, and adjuvant technologies that enhance vaccine efficacy, safety, and ease of administration.
For instance, in June 2021, Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus toxoids vaccine) in the U.S. VAXELIS is a type of combination vaccine to help in prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and other invasive diseases.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of tetanus toxoid vaccine reached USD 5 billion in 2023 and is set to cross USD 8.2 billion by 2032, owing to escalating incidence of tetanus and diphtheria in several countries leading to rising demand for vaccines worldwide.

The tetanus, diphtheria, and pertussis (Tdap) segment is poised to register 6.3% CAGR from 2024 to 2032, due to increased government initiatives to control diphtheria, tetanus, and pertussis.

North America market was valued at USD 2 billion in 2023, attributed to favorable regulatory environment coupled with the growing prevalence of tetanus and diphtheria in the region.

Biological E. Limited, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec, Pfizer Inc., Sanofi, Serum Institute of India, and Zydus Group, are some of the major tetanus toxoid vaccine companies worldwide.